National Academies Press: OpenBook

The Drug Development Paradigm in Oncology: Proceedings of a Workshop (2018)

Chapter: Appendix B: Workshop Agenda

« Previous: Appendix A: Statement of Task
Suggested Citation:"Appendix B: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2018. The Drug Development Paradigm in Oncology: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/24742.
×

Appendix B

Workshop Agenda

December 12, 2016

7:30 am Registration
8:00 am Welcome and Overview of the Workshop
Richard L. Schilsky, American Society of Clinical Oncology Planning Committee Chair
8:10 am Session 1: Vision for a Seamless Cancer Drug Development Paradigm
Moderator: Richard L. Schilsky, American Society of Clinical Oncology
  • Mark Ratain, The University of Chicago
  • Mace Rothenberg, Pfizer Inc.
  • Janet Woodcock, Food and Drug Administration
  • Ellen Sigal, Friends of Cancer Research
Panel Discussion
10:00 am Break
Suggested Citation:"Appendix B: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2018. The Drug Development Paradigm in Oncology: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/24742.
×
10:15 am Session 2: Case Studies and Lessons Learned from Recent Experiences
Moderator: Suzanne Topalian, Johns Hopkins University
Anti-PD-1 Immunotherapy
  • Eric Rubin, Merck
BRAF Pathway Inhibitors
  • Keith Flaherty, Massachusetts General Hospital
T790M EGFR Inhibitors
  • Pasi Jänne, Dana-Farber Cancer Institute
Challenges Resulting from Rapid Regulatory Approvals
  • Donald Harvey, Emory University
Panel Discussion – Session speakers and
  • Gideon Blumenthal, Food and Drug Administration
12:15 pm Lunch
1:00 pm Session 3: Flexible Drug Development and Decision Making: Accommodating New Insights
Moderator: Mace Rothenberg, Pfizer Inc.
Understanding Biological Activity to Inform Drug Development
  • Kenneth Anderson, Dana-Farber Cancer Institute
  • Wolfgang Weber, Memorial Sloan Kettering Cancer Center
Assessing Early Signals of Efficacy to Guide Clinical Development
  • David Feltquate, Bristol-Myers Squibb
  • Richard Finn, University of California, Los Angeles, Jonsson Comprehensive Cancer Center
Dose-Finding Considerations and Strategies for Novel Combination Development
  • Steven Piantadosi, Cedars-Sinai Medical Center
Suggested Citation:"Appendix B: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2018. The Drug Development Paradigm in Oncology: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/24742.
×
Panel Discussion – Session speakers and
  • Patricia Keegan, Food and Drug Administration
  • Hedvig Hricak, Memorial Sloan Kettering Cancer Center
3:15 pm Break
3:30 pm Session 4: Continuous Evidence Generation Across the Cancer Therapy Life Cycle
Moderator: Monica Bertagnolli, Dana-Farber Cancer Institute
Clinical Trial Designs to Expedite Drug Development
  • Mary Redman, Fred Hutchinson Cancer Research Center
  • Rajeshwari Sridhara, Food and Drug Administration
The Use of Real-World Evidence in Drug Development
  • Maria Koehler, Pfizer Inc.
  • Amy Abernethy, Flatiron Health
Panel Discussion – Session speakers and
  • Jeffrey Brown, Harvard Pilgrim Health Care Institute
5:30 pm Wrap-Up of Day 1
Richard L. Schilsky, American Society of Clinical Oncology

December 13, 2016

7:30 am Registration
8:00 am The National Cancer Moonshot Initiative and Seamless Drug Development
Moderator: Richard L. Schilsky, American Society of Clinical Oncology
Blue Ribbon Panel Recommendations
  • Elizabeth Jaffee, Johns Hopkins University
Q&A
Suggested Citation:"Appendix B: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2018. The Drug Development Paradigm in Oncology: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/24742.
×
8:30 am Session 5: Managing Benefit and Risk in Seamless Cancer Drug Development
Moderator: Rebecca Pentz, Emory University School of Medicine
Food and Drug Administration Perspectives on Seamless Drug Development
  • Marc Theoret, Food and Drug Administration
Expanding Eligibility Criteria and Access to Experimental Therapies
American Society of Clinical Oncology, Friends of Cancer Research, and the Food and Drug Administration Working Group to Expand Eligibility Criteria
  • Gwynn Ison, Food and Drug Administration
Expanded Access Programs
  • Steven Lemery, Food and Drug Administration
Patient Protections and Ethical Considerations
  • Steven Joffe, University of Pennsylvania
Data Monitoring Approaches in a Seamless Drug Development Paradigm
  • Frank Rockhold, Duke Clinical Research Institute
Benefit–Risk Analysis of Decision Making in Oncology
  • G. K. Raju, Massachusetts Institute of Technology
Panel Discussion
11:15 am Break
11:30 am Session 6: Stakeholder Perspectives: Goals of the New Paradigm and Priorities for the Path Forward
Moderator: Steven Piantadosi, Cedars-Sinai Medical Center
  • Howard A. Burris, III, Sarah Cannon Research Institute
  • Elizabeth Jaffee, Johns Hopkins University
Suggested Citation:"Appendix B: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2018. The Drug Development Paradigm in Oncology: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/24742.
×
  • Lynn M. Matrisian, Pancreatic Cancer Action Network
  • Eric Rubin, Merck
  • Amy McKee, Food and Drug Administration
  • Jeffrey Brown, Harvard Pilgrim Health Care Institute
  • Rebecca Pentz, Emory University School of Medicine
  • Ronald Kline, Centers for Medicare & Medicaid Services
12:45 pm Wrap-Up of the Workshop
Richard L. Schilsky, American Society of Clinical Oncology Planning Committee Chair
1:00 pm Adjourn
Suggested Citation:"Appendix B: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2018. The Drug Development Paradigm in Oncology: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/24742.
×

This page intentionally left blank.

Suggested Citation:"Appendix B: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2018. The Drug Development Paradigm in Oncology: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/24742.
×
Page 117
Suggested Citation:"Appendix B: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2018. The Drug Development Paradigm in Oncology: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/24742.
×
Page 118
Suggested Citation:"Appendix B: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2018. The Drug Development Paradigm in Oncology: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/24742.
×
Page 119
Suggested Citation:"Appendix B: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2018. The Drug Development Paradigm in Oncology: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/24742.
×
Page 120
Suggested Citation:"Appendix B: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2018. The Drug Development Paradigm in Oncology: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/24742.
×
Page 121
Suggested Citation:"Appendix B: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2018. The Drug Development Paradigm in Oncology: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/24742.
×
Page 122
The Drug Development Paradigm in Oncology: Proceedings of a Workshop Get This Book
×
Buy Paperback | $55.00 Buy Ebook | $44.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

Advances in cancer research have led to an improved understanding of the molecular mechanisms underpinning the development of cancer and how the immune system responds to cancer. This influx of research has led to an increasing number and variety of therapies in the drug development pipeline, including targeted therapies and associated biomarker tests that can select which patients are most likely to respond, and immunotherapies that harness the body’s immune system to destroy cancer cells. Compared with standard chemotherapies, these new cancer therapies may demonstrate evidence of benefit and clearer distinctions between efficacy and toxicity at an earlier stage of development. However, there is a concern that the traditional processes for cancer drug development, evaluation, and regulatory approval could impede or delay the use of these promising cancer treatments in clinical practice. This has led to a number of efforts—by patient advocates, the pharmaceutical industry, and the Food and Drug Administration (FDA)—to accelerate the review of promising new cancer therapies, especially for cancers that currently lack effective treatments. However, generating the necessary data to confirm safety and efficacy during expedited drug development programs can present a unique set of challenges and opportunities.

To explore this new landscape in cancer drug development, the National Academies of Sciences, Engineering, and Medicine developed a workshop held in December 2016. This workshop convened cancer researchers, patient advocates, and representatives from industry, academia, and government to discuss challenges with traditional approaches to drug development, opportunities to improve the efficiency of drug development, and strategies to enhance the information available about a cancer therapy throughout its life cycle in order to improve its use in clinical practice. This publication summarizes the presentations and discussions from the workshop.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!